Connecticut Expands Its Psychedelic Therapy Pilot Program Ahead of Possible Federal Approval
Connecticut is preparing for a future in which psychedelic assisted therapy may move closer to mainstream medicine. Gov. Ned Lamont has signed Senate Bill 191, a measure that expands the state’s existing psychedelic therapy pilot program and protects it from ending if federal approval arrives for MDMA or psilocybin treatment.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and  ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key Point | What It Means |
|---|---|
| The bill expands eligibility | Adults 18 and older may qualify if they meet clinical criteria. |
| The program remains research based | Treatment would still happen in a controlled clinical setting. |
| Veterans and first responders remain a priority | The original focus does not disappear under the new law. |
| Connecticut is planning for federal change | The state wants its program to continue if federal approval comes. |
| The bill does not legalize psychedelics broadly | It applies to a supervised therapy pilot program, not general use. |
What The New Law Changes
Connecticut created its psychedelic therapy pilot program in 2022. The original effort focused on veterans, retired first responders, and direct health care workers with serious mental health needs.
The new law broadens that framework. Adults 18 and older may become eligible if they meet criteria set by the institutional review board at the medical school administering the program.
That change matters because recruitment has been a challenge. Supporters said the program needs more flexibility to enroll enough participants and generate useful data.
The treatment would still take place in a clinical research setting. The bill does not create retail access, personal possession rights, or a broad legalization model.
Why Federal Approval Matters
The timing is important. Federal regulators continue to review psychedelic therapies, including MDMA and psilocybin, for conditions such as post traumatic stress and treatment resistant depression.
Connecticut’s old law included language that could have ended the pilot program if federal authorities approved one of these treatments. Lawmakers worried that would undercut the state’s investment just as the field entered a more serious phase.
The new law removes that problem. Connecticut can keep studying psychedelic assisted therapy even if federal policy changes.
That gives the state more room to build clinical experience, track outcomes, and prepare providers for a future where these treatments may become more available.
A Controlled Step, Not A Free For All
Supporters framed the bill as a mental health measure, not a drug policy free for all. That distinction matters.
Psychedelic therapy depends on screening, preparation, monitored dosing, and integration. The drug experience is only one part of the model. The clinical structure around it often matters just as much.
For patients with severe depression or trauma, that structure may offer a path when conventional treatments have not worked. But it also requires safeguards, trained professionals, and clear rules.
Connecticut is trying to build that system before the demand grows.
What Comes Next
The law takes effect as the national conversation around psychedelic medicine keeps accelerating.
For clinics, researchers, and patients watching this space, Connecticut offers a useful case study. The state is not waiting for full federal clarity before preparing. It is also not abandoning medical oversight.
That middle path may become more common. As psychedelic therapies move through the approval process, states will need to answer practical questions about access, training, safety, and cost.
Connecticut has now made its answer clearer: study the treatments, widen eligibility carefully, and keep the program alive long enough to learn something useful.
